Statistics on Five-Year Survival Rates for Children with Neuroblastoma
Any discussion of prognosis or outlook is usually based on five-year survival rates, or the percentage of children with a specific type of cancer who live at least five years after their initial diagnosis. These numbers are based on studies performed at least five years ago, and so may not reflect improvement in treatment options for some types of cancers. Moreover, these numbers are merely averages and do not indicate the outlook or prognosis for your specific child. Your child’s oncologist will be able to give you a better understanding of your child’s unique case based on his or her type of cancer, age, general health, and response to treatment.
Staging and Prognosis Factors for Neuroblastoma
Five-year survival rates for neuroblastoma are based on a complex system that involves a detailed understanding of the stage of the disease at diagnosis and a series of “prognosis factors”. Currently, statistics on survival rates for neuroblastoma are maintained by the Children’s Oncology Group (COG), which classifies all cases of neuroblastoma into three risk groups: low risk, intermediate risk, and high risk. These risk grouping are based the disease’s stage and prognosis factors.
Staging: There are two different methodologies to determine the stage of disease, or how far the disease has spread beyond the site of the original tumor:
- INRGSS: International Neuroblastoma Risk Group Staging System utilizes the results of imaging tests such CT, MRI, or MIBG scans and can be determined before treatment has begun.
- INSS: International Neuroblastoma Staging System assesses staging after surgery to remove the tumor is performed.
Prognosis factors: these are certain markers that can indicate whether a specific neuroblastoma may respond better or worse to treatment, and can impact a child’s long-term outlook. Specific prognosis factors used to help assign risk for neuroblastoma are:
- Age: children under 12-18 months tend to have a better long-term outlook than older children
- Tumor histology: when examined under a microscope, tumors that contain more normal-looking cells tend to have a better prognosis (favorable histology v. unfavorable histology)
- DNA ploidy: in young children, neuroblastoma cells that contain the same amount of DNA as normal cells (a DNA index of 1, or diploid) seem to respond less favorably to treatment than those that have an increased amount of DNA (a DNA index greater than 1, or hyperdiploid).
- MYCN gene amplifications: neuroblastomas with too many copies of the MYCN oncogene (a gene that helps regulate cell growth and division) seem to grow more quickly and respond less well to treatment.
- Chromosome changes: scientists are just now beginning to understand how the presence or lack thereof of certain chromosomes with the DNA structure of the cells can impact the prognosis for neuroblastoma.
- Neurotrophin (nerve growth factor) receptors: Neurotrophin is a chemical that helps nerve cells mature. Neuroblastomas that have more neurotrophin receptors, especially those receptors called TrkA, are associated with a better long-term outlook.
Five-Year Survival Rates by Risk Group (COG Risk Groupings)
Low Risk: Children whose neuroblastoma is considered “low risk” have a five-year survival rate that is higher than 95%. The low risk group incorporates children who fall into the following categories:
- All Stage 1 diagnoses
- Stage 2A or 2B and under 1 year of age
- Stage 2A or 2B, older than 1 year of age, with 0 extra copies of the MYCN gene
- Stage 2A or 2B, older than 1 year of age, with extra copies of the MYCN gene and a favorable histology
- Stage 4S with favorable histology, hyperdiploid, and no extra copies of the MYCN gene
Intermediate Risk: Children whose neuroblastoma is considered “intermediate risk” have a five-year survival rate of 90-95%. The intermediate risk group incorporates children who fall into the following categories:
- Stage 3, under 1 year of age, no extra copies of the MYCN gene
- Stage 3, greater than 1 year of age, no extra copies of the MYCN gene and a favorable histology
- Stage 4, under 1 year of age, no extra copies of the MYCN gene
- Stage 4S, no extra copies of the MYCN gene and has normal DNA ploidy and/or has an unfavorable histology
High Risk: Children whose neuroblastoma is high risk have a five-year survival rate of 40-50%.
- Stage 2A or 2B, over 1 year old, with extra copies of the MYCN gene and an unfavorable histology
- Stage 3, under a year old, with extra copies of the MYCN gene
- Stage 3, over a year old, with extra copies of the MYCN gene
- Stage 3 and over 18 months old, with an unfavorable histology
- Stage 4 with extra copies of the MYCN gene
- Stage 4 and over 18 months old
- Stage 4, between 12 and 18 months old, with extra copies of the MYCN gene, unfavorable histology, and/or a DNA index of 1
- Stage 4S with extra copies of the MYCN gene
More about Childhood Neuroblastoma Cancers:
- About Childhood Neuroblastoma Cancer – Detection and Diagnosis
- Causes, Risk Factors, and Prevention of Childhood Neuroblastoma Cancer
- What are the signs and symptoms of Childhood Neuroblastoma Cancer?
- Childhood Neuroblastoma Cancer Treatment
- Childhood Neuroblastoma Cancer – Stages and Prognosis
- What is the expected life span of Childhood Neuroblastoma Cancer?
- After Treatment – Living as a Childhood Neuroblastoma Cancer Survivor
Learn More About the Different Types of Childhood Cancers:
- Childhood Brain Tumor Cancer (Brain Stem Tumors)
- Spinal Cord Tumor Cancer
- Childhood Neuroblastoma Cancers
- Childhood Hodgkin Lymphoma Cancers
- Non-Hodgkin Lymphoma Cancers
- Wilms tumor (Kidney Tumors)
- Bone cancer (including osteosarcoma and Ewing sarcoma)
- Leukemia Cancers: Acute lymphocytic (lymphoblastic) leukemia (ALL) Acute myelogenous leukemia (AML); Juvenile myelomonocytic leukemia (JMML)
- Hepatoblastoma (Liver Cancer)
- Rhabdoid Tumors
About American Childhood Cancer Organization
American Childhood Cancer Organization (ACCO) is a non-profit charity dedicated to helping kids with cancer and their families navigate the difficult journey from cancer diagnosis through survivorship. Internationally, ACCO is the sole U.S. member of Childhood Cancer International (CCI), the largest patient-support organization for childhood cancer in the world. Here in the United States, ACCO promotes the critical importance of ensuring continued funding into new and better treatment protocols for childhood cancer. And most importantly, ACCO is focused on the children: developing and providing educational tools for children fighting cancer and their families, empowering them in their understanding of childhood cancer and the medical decisions they must make during this difficult journey. All of ACCO’s resources are available free of charge for families coping with childhood cancer.
For additional information about childhood cancer or on ACCO, or to order resources for you or your child, please visit our website at www.acco.org.